Press Releases BELLUS Health

Equities

BLU

CA07987C2040

Market Closed - Toronto S.E. Other stock markets 16:00:00 2023-06-29 EDT			5-day change	1st Jan Change
19.48 ^CAD	-0.10%		-.--%	-.--%

2023	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Capped Composite Index	CI
2023	BELLUS Health Inc.(TSX:BLU) dropped from S&P/TSX Completion Index	CI

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BELLUS Health : MATERIAL CHANGE REPORT - Form 6-K	23-06-28	PU
GSK completes acquisition of BELLUS Health \| GSK	23-06-28	AQ
Stock-exchange announcement - For media and investors only - GSK completes acquisition of BELLUS Health	23-06-28	AQ
BELLUS Health Inc. Announces Voting Results from Special Meeting of Shareholders	23-06-16	BU
BELLUS Health : NOTICE OF ANNUAL AND SPECIAL MEETING OF SHAREHOLDERS - Form 6-K	23-06-06	PU
BELLUS Health : AMENDED AND RESTATED MANAGEMENT INFORMATION CIRCULAR FOR THE ANNUAL AND SPECIAL MEETING OF COMMON SHAREHOLDERS TO BE HELD ON JUNE 30, 2023 - Form 6-K	23-06-02	PU
BELLUS Health : Forms of Proxy	23-05-31	PU
BELLUS Health : Amended and Restated Management Information Circular dated May 31, 2023	23-05-30	PU
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights	23-05-15	AQ
Bellus: Q1 Earnings Snapshot	23-05-12	AQ
BELLUS Health Reports First Quarter 2023 Financial Results and Business Highlights	23-05-12	BU
BELLUS Health : Notice of the Meeting and Record Date - Form 6-K	23-04-28	PU
BELLUS Health Announces Meeting Updates	23-04-26	BU
BELLUS Health : Notice of the Meeting and Record Date - Form 6-K	23-04-25	PU
GSK coughs up £1.6bn for Bellus in bid to boost medicine cabinet	23-04-19	AQ
Southwest Airlines, XCel Brands fall; Lockheed, Bellus rise	23-04-18	AQ
GSK reaches agreement to acquire late-stage biopharmaceutical company BELLUS Health \| GSK	23-04-18	AQ
GSK signs deal to buy Canadian drug developer Bellus Health for US$2 billion	23-04-18	AQ
GSK to acquire BELLUS for £1.6 billion	23-04-18	AQ
BELLUS Health Announces Positive Results from its Phase 1 Bioavailability Equivalence Study Evaluating Once-Daily Extended-Release Formulation of Camlipixant in Comparison to Twice-Daily Immediate Release Formulation	23-04-05	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases BELLUS Health

Equities

BLU

CA07987C2040

Press Releases

Filters